Results 191 to 200 of about 10,665,939 (329)

Serum Chitotriosidase Links to Activated Glia at Chronic Active Lesion Rims in Multiple Sclerosis Brain

open access: yesAnnals of Neurology, EarlyView.
Objective The objective of this study was to explore the association between 18 kDa translocator protein (TSPO)‐positron emission tomography (PET)–measurable glial activation and serum chitotriosidase (CHIT1) in people with multiple sclerosis (pwMS), and its expression in postmortem MS brain tissue.
Venla Ahola   +14 more
wiley   +1 more source

Cerebral No‐Reflow after Thrombectomy: International Delphi Consensus on Definition and Imaging Assessment

open access: yesAnnals of Neurology, EarlyView.
Background The operational definition and imaging assessment of the no‐reflow phenomenon, a potential contributor to poor clinical outcome despite successful thrombectomy, remains debated. We aimed to develop expert‐based international consensus on the definition, assessment, and reporting standard of cerebral no‐reflow post‐thrombectomy. Methods Three‐
Adnan Mujanovic   +21 more
wiley   +1 more source

Centrum Semiovale Perivascular Spaces Predict First Hemorrhagic Lesion in Asymptomatic Amyloid‐Positive Individuals

open access: yesAnnals of Neurology, EarlyView.
Objective Identification of cerebral amyloid angiopathy (CAA) before its hemorrhagic manifestations remains limited. We aimed to determine whether severe enlarged perivascular spaces in the centrum semiovale (EPVS‐CSO) identify a prehemorrhagic stage of sporadic CAA by predicting the first appearance of CAA‐related hemorrhagic lesions or incident ...
Baris Alten   +8 more
wiley   +1 more source

Sleep quality and chronotype in primary headache disorders: a nationwide population-based study of 5,311 Polish adults. [PDF]

open access: yesJ Headache Pain
Marschollek K   +4 more
europepmc   +1 more source

Astrocyte SMN Restoration and Forskolin Treatment Improve SMA Synaptic Pathology

open access: yesAnnals of Neurology, EarlyView.
Objective Early phenotypic presentation of central afferent synapse dysfunction within patients with spinal muscular atrophy (SMA) represents a key target for therapeutic development; however, the underlying disease mechanisms remain unresolved. By further investigating motor neuron synapse and peri‐synaptic astrocyte process (PAP) defects in human SMA
Emily Welby   +6 more
wiley   +1 more source

Texture analysis on muscle T2 maps can reveal changes in upper trapezius muscles related to primary headache disorders. [PDF]

open access: yesSci Rep
Sollmann N   +13 more
europepmc   +1 more source

Primary headache management in a multidisciplinary team - a pilot study. [PDF]

open access: yesJ Med Life, 2023
Mihaiu J   +4 more
europepmc   +1 more source

A critical reappraisal of the carotid sinus and carotid bulb: Distinguishing neurohistological function from vascular geometry

open access: yesThe Anatomical Record, EarlyView.
This review redefines the carotid bulb (CB) as a variable geometric dilation shaped by hemodynamics and the carotid sinus (CS) as a conserved neurohistological baroreceptor field. Distinguishing these entities clarifies a century of anatomical confusion and links geometry, neurohistology, and clinical interpretation within a unified framework ...
Răzvan Costin Tudose   +2 more
wiley   +1 more source

Editorial: Cognitive schemas in primary headache disorders. [PDF]

open access: yesFront Neurol, 2023
Özge A   +3 more
europepmc   +1 more source

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy